PAK6 and chronic myelogenous leukemia, BCR-ABL1 positive: It is also associated with P21 (RAC1)-activated kinase 6 (PAK6), inhibition of which has been shown to sensitize therapy-resistant cells to tyrosine kinase inhibitors in chronic myeloid leukemia by disrupting the RAS/MAPK pathway and mitochondrial activity [86].